Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 1, 2015, Pages 21.e11-21.e17

  Kaffenberger, Samuel D ^a   Lin Tsai, Opal ^b   Stratton, Kelly L ^a,c   Morgan, Todd M ^a,d   Barocas, Daniel A ^a   Chang, Sam S ^a   Cookson, Michael S ^e   Herrell, S Duke ^a   Smith, Joseph A ^a   Clark, Peter E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Nephrectomy; Partial nephrectomy; Renal cell carcinoma; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD GROUP O; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHARLSON COMORBIDITY INDEX; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; HYPOALBUMINEMIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX RATIO; VERY ELDERLY; CARCINOMA, RENAL CELL; EPIDEMIOLOGY; KIDNEY NEOPLASMS; MORTALITY; NEPHRECTOMY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SURVIVAL ANALYSIS; TENNESSEE; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TENNESSEE; TREATMENT OUTCOME;

EID: 84922628801     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.10.007     Document Type: Article

References (29)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Ljungberg B., Cowan N.C., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
3. Karakiewicz P.I., Suardi N., Capitanio U., Jeldres C., Ficarra V., Cindolo L., et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2009, 55:287-295.
4. Kutikov A., Egleston B.L., Wong Y.N., Uzzo R.G. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010, 28:311-317.
5. Morgan T.M., Tang D., Stratton K.L., Barocas D.A., Anderson C.B., Gregg J.R., et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011, 59:923-928.
6. Kaffenberger S.D., Morgan T.M., Stratton K.L., Boachie A.M., Barocas D.A., Chang S.S., et al. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int 2012, 110:E641-E646.
7. Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., Guchelaar H.J. The risk of cancer in users of statins. J Clin Oncol 2004, 22:2388-2394.
8. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., et al. Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-2192.
9. Cauley J.A., McTiernan A., Rodabough R.J., LaCroix A., Bauer D.C., Margolis K.L., et al. Statin use and breast cancer: prospective results from the Women[U+05F3]s Health Initiative. J Natl Cancer Inst 2006, 98:700-707.
10. Platz E.A., Leitzmann M.F., Fisvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006, 98:1819-1825.
11. Khurana V., Caldito G., Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 2008, 71:118-122.
12. Liu W., Choueiri T.K., Cho E. Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer 2012, 118:797-803.
13. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med 2012, 367:1792-1802.
14. Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19.
15. Wong W.W., Dimitroulakos J., Minden M.D., Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 16:508-519.
16. Woodard J., Sassano A., Hay N., Platanias L.C. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res 2008, 14:4640-4649.
17. Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012, 18:3524-3531.
18. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., White C.M. Statins and cancer risk: a meta-analysis. J Am Med Assoc 2006, 295:74-80.
19. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
20. Ng K., Ogino S., Meyerhardt J.A., Chan J.A., Chan A.T., Niedzwiecki D., et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 2011, 103:1540-1551.
21. Friedman G.D., Flick E.D., Udaltsova N., Chan J., Quesenberry C.P., Habel L.A. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008, 17:27-36.
22. Chiu H.F., Kuo C.C., Kuo H.W., Lee I.M., Lee C.T., Yang C.Y. Statin use and the risk of kidney cancer: a population-based case-control study. Expert Opin Drug Saf 2012, 11:543-549.
23. Hamilton R.J., Morilla D., Cabrera F., Leapman M., Chen L.Y., Bernstein M., et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol 2014, 191:914-919.
24. Linehan W.M., Srinivasan R., Schmidt L.S. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010, 7:277-285.
25. Paraskevas K.I., Tzovaras A.A., Briana D.D., Mikhailidis D.P. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 2007, 13:3622-3636.
26. Bil J., Zapala L., Nowis D., Jakobisiak M., Golab J. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett 2010, 288:57-67.
27. Horiguchi A., Sumitomo M., Asakuma J., Asano T., Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004, 10:8648-8655.
28. Cho D., Signoretti S., Regan M., Mier J.W., Atkins M.B. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007, 13:758s-763s.
29. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.